Cynvenio to Present at the 103rd American Association for Cancer Research (AACR) Annual Meeting on its Proprietary CTC Isolation Flow Cell and the Workflow for the Analysis of DNA Mutations in CTC

Westlake Village, CA — March 25, 2012—Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research in circulating tumor cells, personalized medicine and the molecular diagnostics of cancer, today announced that it will be presenting a poster at the 103rd Annual Meeting of the American Association for Cancer Research taking place at the McCormick Center in Chicago, next week. The presentation will describe Cynvenio’s proprietary Circulating Tumor Cell (CTC) isolation flow cell and the workflow for the analysis of DNA mutations in circulating tumor cells (CTC).

The Cynvenio presentation entitled “Q-PCR and Sequence Analysis of DNA Template from a Microfluidic CTC Isolation Platform” will take place on April 3rd from 1pm to 5pm in the “Imaging and Molecular Diagnostics” category (Abstract 4554). Cynvenio’s CTC platform provides a technology and workflow to reliably detect and recover limiting numbers of CTCs from a simple blood draw. By enabling sequence analysis and quantitative PCR profiling, the platform for the first time provides a tool to demonstrate the utility of mutation-bearing CTC in patient care. Using model CTC systems, PCR analysis could be used to detect mutations in as few as 3-5 cells recovered from 2 mL of whole blood. Sequence analysis of a panel of more than 200 cancer-related genes could detect multiple somatic mutations from as few as 10 cancer cells. This workflow was tested on patients with locally advanced breast cancer. The CTC flow cell technology yielded CTC from 16 of 17 samples. The specificity of the CTC purification allowed high throughput sequencing analysis of these patients revealing familiar cancer associated mutation in 4/12 patients including mutations in TP53, KRAS, FLT4, JAK3 and MUTYH. These data suggest CTC represent a viable substrate for minimally-invasive tumor sequencing made possible by the purity and specificity of this platform. A robust and reliable platform to functionally access this population of cells is necessary to perform the clinical correlation studies necessary to allow serial tumor sampling by CTC mutation analysis in patients.

About Cynvenio Biosystems, Inc.

Cynvenio Biosystems, Inc. is a privately held company focused on the development of the LiquidBiopsy™ platform, a high performance rare cell isolation technology for biomedical research and novel cancer diagnostics. As a precursor to next generation sequencing and the mutational profiling of cancer cells retrieved from whole blood, LiquidBiopsy™ is a key enabling technology to realize the promise of personalized medicine – including the early detection of disease, real time monitoring of patients, and the selection of individual therapeutic solutions. Cynvenio is based in Westlake Village, California. Find more information at www.cynvenio.com